Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 December 2007, Vol. 110, No. 13, pp. 4436-4444.
Prepublished online as a Blood First Edition Paper on September 4, 2007; DOI 10.1182/blood-2007-05-088815.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
blood-2007-05-088815v1
110/13/4436    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guzman, M. L
Right arrow Articles by Jordan, C. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guzman, M. L
Right arrow Articles by Jordan, C. T.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted May 7, 2007
Accepted August 29, 2007

Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)

Monica L Guzman*, Xiaojie Li, Cheryl A Corbett, Randall M Rossi, Timothy Bushnell, Jane L Liesveld, Josee Hebert, Fay Young, and Craig T. Jordan

James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, United States
Quebec Leukemia Cell Bank, Centre de Recherche Guy-Bernier, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada

* Corresponding author; email: monica_guzman{at}urmc.rochester.edu.

Leukemia is thought to arise from malignant stem cells, which have been described for acute and chronic myeloid leukemia (AML and CML), and for acute lymphoblastic leukemia (ALL). Leukemia stem cells (LSCs) are relatively resistant to current chemotherapy and likely contribute to disease relapse and progression. Consequently, the identification of drugs that can efficiently eradicate LSCs is an important priority. In the present study, we investigated the anti-leukemia activity of the compound TDZD-8. Analysis of primary AML, CML, ALL, and CLL specimens demonstrated rapid induction of cell death upon treatment with TDZD-8. In addition, for myeloid leukemias, cytotoxicity was observed for phenotypically primitive cells, in vitro colony-forming progenitors, and LSCs as defined by xenotransplantation assays. In contrast, no significant toxicity was observed for normal hematopoietic stem and progenitor cells. Notably, cell death was frequently evident within 2 hours or less of TDZD-8 exposure. Cellular and molecular studies indicate that the mechanism by which TDZD-8 induces cell death involves rapid loss of membrane integrity, depletion of free thiols, and inhibition of both the PKC and FLT3 signaling pathways. We conclude that TDZD-8 employs a unique and previously unknown mechanism to rapidly target leukemia cells, including malignant stem and progenitor populations.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

LSC defenses breached by chemical arsenal
Tessa L. Holyoake and Mhairi Copland
Blood 2007 110: 4138-4139. [Full Text] [PDF]



This article has been cited by other articles:


Home page
BloodHome page
M. Rahmani, A. Anderson, J. R. Habibi, T. R. Crabtree, M. Mayo, H. Harada, A. Ferreira-Gonzalez, P. Dent, and S. Grant
The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways
Blood, November 12, 2009; 114(20): 4507 - 4516.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. E. Dick
Stem cell concepts renew cancer research
Blood, December 15, 2008; 112(13): 4793 - 4807.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. E. Khuda, W. M. Loo, S. Janz, B. Van Ness, and L. D. Erickson
Deregulation of c-Myc Confers Distinct Survival Requirements for Memory B Cells, Plasma Cells, and Their Progenitors
J. Immunol., December 1, 2008; 181(11): 7537 - 7549.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. C. Hassane, M. L. Guzman, C. Corbett, X. Li, R. Abboud, F. Young, J. L. Liesveld, M. Carroll, and C. T. Jordan
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data
Blood, June 15, 2008; 111(12): 5654 - 5662.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Copland, F. Pellicano, L. Richmond, E. K. Allan, A. Hamilton, F. Y. Lee, R. Weinmann, and T. L. Holyoake
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors
Blood, March 1, 2008; 111(5): 2843 - 2853.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
C. H. Jamieson
Chronic Myeloid Leukemia Stem Cells
Hematology, January 1, 2008; 2008(1): 436 - 442.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020